Anti-CD38 (eg, daratumumab) as part of a combination regimen or as a monotherapy Subjects who were not candidates to receive one or more of the above treatments (ie, contraindicated) are eligible.
Any prior therapy with daratumumab
Received daratumumab or other anti-CD38 therapies previously
Subject has received daratumumab or other anti-CD38 therapies previously
SY-1425 and daratumumab combination only - Prior or concurrent exposure to daratumumab or other CD38 therapies5.
SY-1425 and daratumumab combination only - Subject has either of the following:
Prior treatment with anti-CD38 therapy including daratumumab (Cohorts D1, D2, E, F)
Have received prior ixazomib at any time or daratumumab or other anti-CD38 therapies, except as part of initial therapy if this was stopped to move on to SCT and the participants did not progress on anti-CD38 treatment.
Prior daratumumab or other anti-CD38 antibody
Cancer chemotherapy within 2 weeks prior to start of daratumumab treatment (steroid or hydroxyurea can be used up to 24 hours prior to first daratumumab infusion for control of high white cell counts)
Has received prior treatment with daratumumab or other anti-CD38 therapies previously
Previously received daratumumab or other anti-CD38 therapies
Participant has received daratumumab or other anti-cluster of differentiation 38 (anti-CD38) therapies previously
Has received daratumumab or other anti-CD38 therapies previously
Anti-cluster of differentiation(CD)38 therapy, including daratumumab
Has received any of the following therapies: daratumumab or other anti-CD38 therapies
Disease progression on daratumumab
Previous therapy with daratumumab or other anti-CD38 monoclonal antibodies.
Daratumumab or other anti-CD38 therapies
Prior exposure to daratumumab or prior exposure to other anti-Cluster of Differentiation 38 (anti-CD38) therapies
Daratumumab or other anti CD38 antibody treatment within 3 months prior to study enrollment
